BioCentury
ARTICLE | Clinical News

Novartis presents Phase II data on Glivec

December 4, 2000 8:00 AM UTC

Novartis (SWX:NOVN; NVS) announced Phase II data from 3 separate studies of Glivec (STI571), an inhibitor of the Bcr-Abl tyrosine kinase, to treat leukemias involving the presence of Philadelphia chro...